JP2016516513A - リン酸カルシウムセメント組成物 - Google Patents
リン酸カルシウムセメント組成物 Download PDFInfo
- Publication number
- JP2016516513A JP2016516513A JP2016509243A JP2016509243A JP2016516513A JP 2016516513 A JP2016516513 A JP 2016516513A JP 2016509243 A JP2016509243 A JP 2016509243A JP 2016509243 A JP2016509243 A JP 2016509243A JP 2016516513 A JP2016516513 A JP 2016516513A
- Authority
- JP
- Japan
- Prior art keywords
- calcium phosphate
- calcium
- cement composition
- composition according
- component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 title claims abstract description 122
- 239000001506 calcium phosphate Substances 0.000 title claims abstract description 78
- 229910000389 calcium phosphate Inorganic materials 0.000 title claims abstract description 75
- 235000011010 calcium phosphates Nutrition 0.000 title claims abstract description 75
- 239000004568 cement Substances 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 239000000843 powder Substances 0.000 claims abstract description 49
- 238000006243 chemical reaction Methods 0.000 claims abstract description 39
- 239000003112 inhibitor Substances 0.000 claims abstract description 22
- 150000001768 cations Chemical class 0.000 claims abstract description 20
- 239000007864 aqueous solution Substances 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000011575 calcium Substances 0.000 claims description 48
- 239000007788 liquid Substances 0.000 claims description 30
- 150000002500 ions Chemical class 0.000 claims description 28
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 24
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims description 20
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 18
- 239000002245 particle Substances 0.000 claims description 17
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 claims description 14
- 229910052586 apatite Inorganic materials 0.000 claims description 12
- 230000005855 radiation Effects 0.000 claims description 12
- 235000011054 acetic acid Nutrition 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 229910052791 calcium Inorganic materials 0.000 claims description 5
- 230000002950 deficient Effects 0.000 claims description 5
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 4
- ZCCIPPOKBCJFDN-UHFFFAOYSA-N calcium nitrate Chemical compound [Ca+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ZCCIPPOKBCJFDN-UHFFFAOYSA-N 0.000 claims description 4
- 159000000007 calcium salts Chemical class 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- RBLGLDWTCZMLRW-UHFFFAOYSA-K dicalcium;phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])([O-])=O RBLGLDWTCZMLRW-UHFFFAOYSA-K 0.000 claims description 4
- 150000004683 dihydrates Chemical class 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
- 229920002674 hyaluronan Polymers 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- 150000004682 monohydrates Chemical class 0.000 claims description 4
- 239000002159 nanocrystal Substances 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- 239000001110 calcium chloride Substances 0.000 claims description 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 3
- -1 dimethylsiloxane Chemical class 0.000 claims description 3
- 229940095064 tartrate Drugs 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- HECLRDQVFMWTQS-UHFFFAOYSA-N Dicyclopentadiene Chemical compound C1C2C3CC=CC3C1C=C2 HECLRDQVFMWTQS-UHFFFAOYSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 claims description 2
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 claims description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 229910000416 bismuth oxide Inorganic materials 0.000 claims description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 2
- 239000001639 calcium acetate Substances 0.000 claims description 2
- 235000011092 calcium acetate Nutrition 0.000 claims description 2
- 229960005147 calcium acetate Drugs 0.000 claims description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 2
- 239000001354 calcium citrate Substances 0.000 claims description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 2
- 239000001527 calcium lactate Substances 0.000 claims description 2
- 235000011086 calcium lactate Nutrition 0.000 claims description 2
- 229960002401 calcium lactate Drugs 0.000 claims description 2
- 239000001362 calcium malate Substances 0.000 claims description 2
- OLOZVPHKXALCRI-UHFFFAOYSA-L calcium malate Chemical compound [Ca+2].[O-]C(=O)C(O)CC([O-])=O OLOZVPHKXALCRI-UHFFFAOYSA-L 0.000 claims description 2
- 229940016114 calcium malate Drugs 0.000 claims description 2
- 235000011038 calcium malates Nutrition 0.000 claims description 2
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 claims description 2
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 claims description 2
- ZOMBKNNSYQHRCA-UHFFFAOYSA-J calcium sulfate hemihydrate Chemical compound O.[Ca+2].[Ca+2].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O ZOMBKNNSYQHRCA-UHFFFAOYSA-J 0.000 claims description 2
- GUPPESBEIQALOS-UHFFFAOYSA-L calcium tartrate Chemical compound [Ca+2].[O-]C(=O)C(O)C(O)C([O-])=O GUPPESBEIQALOS-UHFFFAOYSA-L 0.000 claims description 2
- 239000001427 calcium tartrate Substances 0.000 claims description 2
- 235000011035 calcium tartrate Nutrition 0.000 claims description 2
- HDRTWMBOUSPQON-ODZAUARKSA-L calcium;(z)-but-2-enedioate Chemical compound [Ca+2].[O-]C(=O)\C=C/C([O-])=O HDRTWMBOUSPQON-ODZAUARKSA-L 0.000 claims description 2
- AVVIDTZRJBSXML-UHFFFAOYSA-L calcium;2-carboxyphenolate;dihydrate Chemical compound O.O.[Ca+2].OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O AVVIDTZRJBSXML-UHFFFAOYSA-L 0.000 claims description 2
- PBUBJNYXWIDFMU-UHFFFAOYSA-L calcium;butanedioate Chemical compound [Ca+2].[O-]C(=O)CCC([O-])=O PBUBJNYXWIDFMU-UHFFFAOYSA-L 0.000 claims description 2
- LQHWSGSWNOHVHO-UHFFFAOYSA-L calcium;oxalate;hydrate Chemical compound O.[Ca+2].[O-]C(=O)C([O-])=O LQHWSGSWNOHVHO-UHFFFAOYSA-L 0.000 claims description 2
- JZKWLRKZXVYSKT-UHFFFAOYSA-N calcium;pentanoic acid Chemical compound [Ca].CCCCC(O)=O JZKWLRKZXVYSKT-UHFFFAOYSA-N 0.000 claims description 2
- MLMODXBPCNLAGP-UHFFFAOYSA-L calcium;propanedioate Chemical compound [Ca+2].[O-]C(=O)CC([O-])=O MLMODXBPCNLAGP-UHFFFAOYSA-L 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000000919 ceramic Substances 0.000 claims description 2
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- TYIXMATWDRGMPF-UHFFFAOYSA-N dibismuth;oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Bi+3].[Bi+3] TYIXMATWDRGMPF-UHFFFAOYSA-N 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 150000004687 hexahydrates Chemical class 0.000 claims description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 claims description 2
- 229940099552 hyaluronan Drugs 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 229960004359 iodixanol Drugs 0.000 claims description 2
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 claims description 2
- 229960001025 iohexol Drugs 0.000 claims description 2
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 claims description 2
- 229960004537 ioversol Drugs 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 239000003605 opacifier Substances 0.000 claims description 2
- RVTZCBVAJQQJTK-UHFFFAOYSA-N oxygen(2-);zirconium(4+) Chemical compound [O-2].[O-2].[Zr+4] RVTZCBVAJQQJTK-UHFFFAOYSA-N 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 235000019260 propionic acid Nutrition 0.000 claims description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 2
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 2
- UONOETXJSWQNOL-UHFFFAOYSA-N tungsten carbide Chemical compound [W+]#[C-] UONOETXJSWQNOL-UHFFFAOYSA-N 0.000 claims description 2
- 229920003169 water-soluble polymer Polymers 0.000 claims description 2
- 229910001928 zirconium oxide Inorganic materials 0.000 claims description 2
- 239000001736 Calcium glycerylphosphate Substances 0.000 claims 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 claims 1
- 229940095618 calcium glycerophosphate Drugs 0.000 claims 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 claims 1
- HDRTWMBOUSPQON-TYYBGVCCSA-L calcium;(e)-but-2-enedioate Chemical compound [Ca+2].[O-]C(=O)\C=C\C([O-])=O HDRTWMBOUSPQON-TYYBGVCCSA-L 0.000 claims 1
- 238000010304 firing Methods 0.000 claims 1
- 229940049920 malate Drugs 0.000 claims 1
- 230000009257 reactivity Effects 0.000 abstract description 5
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000011777 magnesium Substances 0.000 description 17
- 239000013078 crystal Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 13
- 239000007924 injection Substances 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000012190 activator Substances 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 6
- 230000000977 initiatory effect Effects 0.000 description 6
- 238000002334 isothermal calorimetry Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 229960005069 calcium Drugs 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 239000003966 growth inhibitor Substances 0.000 description 4
- 230000006911 nucleation Effects 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 101100496858 Mus musculus Colec12 gene Proteins 0.000 description 3
- 230000017525 heat dissipation Effects 0.000 description 3
- 238000005191 phase separation Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000011396 hydraulic cement Substances 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000013383 initial experiment Methods 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000002683 reaction inhibitor Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- GBNXLQPMFAUCOI-UHFFFAOYSA-H tetracalcium;oxygen(2-);diphosphate Chemical compound [O-2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GBNXLQPMFAUCOI-UHFFFAOYSA-H 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- RWYRUDPAALLKPX-UHFFFAOYSA-N 2,2-difluoro-n-methylethanamine;hydrochloride Chemical compound Cl.CNCC(F)F RWYRUDPAALLKPX-UHFFFAOYSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 239000001749 Calcium fumarate Substances 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- AUUMRXMOQLANAM-UHFFFAOYSA-N O.O.[Ca].[Ca].P(O)(O)(O)=O Chemical compound O.O.[Ca].[Ca].P(O)(O)(O)=O AUUMRXMOQLANAM-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 238000010669 acid-base reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000019296 calcium fumarate Nutrition 0.000 description 1
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229910052587 fluorapatite Inorganic materials 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical compound OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- VQNBUJAEBQLLKU-UHFFFAOYSA-H tricalcium;diphosphate;hydrate Chemical compound O.[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VQNBUJAEBQLLKU-UHFFFAOYSA-H 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B12/00—Cements not provided for in groups C04B7/00 - C04B11/00
- C04B12/02—Phosphate cements
- C04B12/025—Phosphates of ammonium or of the alkali or alkaline earth metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/02—Surgical adhesives or cements; Adhesives for colostomy devices containing inorganic materials
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D25/00—Details of other kinds or types of rigid or semi-rigid containers
- B65D25/02—Internal fittings
- B65D25/04—Partitions
- B65D25/08—Partitions with provisions for removing or destroying, e.g. to facilitate mixing of contents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/32—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B40/00—Processes, in general, for influencing or modifying the properties of mortars, concrete or artificial stone compositions, e.g. their setting or hardening ability
- C04B40/06—Inhibiting the setting, e.g. mortars of the deferred action type containing water in breakable containers ; Inhibiting the action of active ingredients
- C04B40/0641—Mechanical separation of ingredients, e.g. accelerator in breakable microcapsules
- C04B40/065—Two or more component mortars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Ceramic Engineering (AREA)
- Materials Engineering (AREA)
- Mechanical Engineering (AREA)
- Organic Chemistry (AREA)
- Structural Engineering (AREA)
- Life Sciences & Earth Sciences (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Dental Preparations (AREA)
Abstract
Description
この例では、2つの成分、即ち、(A)6.0gのα−リン酸三カルシウム粉末(α−TCP、Ca3(PO4)2、SSA値:0.6m2/g、>99%の純度、MgCl2溶液に分散される前に500℃で24時間焼成)および2.6mlの0.1M塩化マグネシウム(MgCl2)溶液の混合物、ならびに(B)0.52mlの5M塩化カルシウム(CaCl2)溶液、からなるリン酸カルシウムセメントの使用について説明する。
種々の組成を有する本発明のリン酸カルシウムセメント組成物のいくつかの試料を、表1に記載したパラメータを用いて、37℃において等温熱量計中で試験した。
本発明のリン酸カルシウムセメント組成物のいくつかの試料を、表2に記載したパラメータを用いて37℃において等温熱量計中で試験した。
本発明の種々の組成物を用いたいくつかのセメント試料を、表1に記載したパラメータを用いて37℃において等温熱量計中で試験した。
本発明の種々の組成物を用いたいくつかのセメント試料を、表3に記載したパラメータを用いて37℃において等温熱量計中で試験した。
Claims (32)
- 以下の2つの成分
A)リン酸カルシウム粉末と水の反応を抑制する抑制剤カチオンを含む水溶液中に懸濁された1つまたはいくつかのリン酸カルシウム粉末であって、抑制剤カチオンは0.01Mより高い濃度のMg2+、Sr2+またはBa2+から選択されるリン酸カルシウム粉末、および
B)0.1Mより高い濃度でCa2+カチオンを含む水溶液
を含むリン酸カルシウムセメント組成物。 - 抑制剤カチオンがMg2+のみから選択される、請求項1に記載のリン酸カルシウムセメント組成物。
- 抑制剤カチオンがSr2+のみから選択される、請求項1に記載のリン酸カルシウムセメント組成物。
- 成分Aと成分Bとの比が、この2つの成分を混合した場合に、混合物中のCa2+イオン/抑制剤カチオンのモル比が2より大きく、好ましくは5より大きくなる、請求項1から3のいずれか一項に記載のリン酸カルシウムセメント組成物。
- リン酸カルシウム粉末がα−リン酸三カルシウムである、請求項1から4のいずれか一項に記載のリン酸カルシウムセメント組成物。
- リン酸カルシウム粉末が非晶質リン酸カルシウム(ACP)である、請求項1から4のいずれか一項に記載のリン酸カルシウムセメント組成物。
- リン酸カルシウム粉末が400℃から700℃の範囲の温度で少なくとも10分焼成することにより得られる、請求項1から5のいずれか一項に記載のリン酸カルシウムセメント組成物。
- 成分A中の抑制剤カチオンの濃度が0.05M以上、好ましくは0.1Mより大きい、請求項1から7のいずれか一項に記載のリン酸カルシウムセメント組成物。
- 成分Bが、0.5Mより大きい、好ましくは1.0Mより大きい溶解度を有する高可溶性カルシウム塩を含む、請求項1から8のいずれか一項に記載のリン酸カルシウムセメント組成物。
- 成分Bが以下のカルシウム塩、即ち、塩化カルシウム(無水:CaCl2、一水和物:CaCl2・H2O、二水和物:CaCl2・2H2O、または六水和物:CaCl2・6H2O)、リン酸二カルシウム二水和物(CaHPO4・2H2O;DCPD)、硫酸カルシウム二水和物(CaSO4・2H2O;CSD)、硫酸カルシウム半水和物(CaSO4・1/2H2O;CSH)、硫酸カルシウム(CaSO4)、硝酸カルシウム、酢酸カルシウム(無水:Ca(C2H3O2)2、一水和物:Ca(C2H3O2)2・H2O、または二水和物:Ca(C2H3O2)2・2H2O)、クエン酸カルシウム(Ca3(C6H5O7)・4H2O)、フマル酸カルシウム(CaC4H2O4・3H2O)、グリセロリン酸カルシウム(CaC3H5(OH2)PO4)、乳酸カルシウム(Ca(C3H5O3)2・5H2O)、リンゴ酸カルシウム(dl−リンゴ酸塩:CaC4H4O5・3H2O、l−リンゴ酸塩:CaC4H4O5・2H2O、またはリンゴ酸二水素:Ca(HC4H4O5)2・6H2O)、マレイン酸カルシウム(CaC4H2O4・H2O)、マロン酸カルシウム(CaC3H2O4・4H2O、)、シュウ酸カルシウム(CaC2O4)、シュウ酸カルシウム水和物(CaC2O4・H2O)、サリチル酸カルシウム(Ca(C7H5O3)2・2H2O)、コハク酸カルシウム(CaC4H6O4・3H2O)、酒石酸カルシウム(d−酒石酸塩:CaC4H4O6・4H2O、dl−酒石酸塩:CaC4H4O6・4H2O、メソ酒石酸塩:CaC4H4O6・3H2O)、ならびに吉草酸カルシウム(Ca(C5H9O2)2)の1つ以上を含む、請求項1から9のいずれか一項に記載のリン酸カルシウムセメント組成物。
- 2つの成分A/Bの体積比が4以上である、請求項1から10のいずれか一項に記載のリン酸カルシウムセメント組成物。
- 2つの成分A/Bの体積比が12未満である、請求項1から11のいずれか一項に記載のリン酸カルシウムセメント組成物。
- 成分B中のCa2+イオンの濃度が0.5Mより高い、請求項1から12のいずれか一項に記載のリン酸カルシウムセメント組成物。
- 成分Bがリン酸カルシウム粉末を含む、請求項1から13のいずれか一項に記載のリン酸カルシウムセメント組成物。
- リン酸カルシウム粉末がアパタイト、好ましくは純粋なヒドロキシアパタイト、SiまたはSr置換アパタイトのようなイオン置換ヒドロキシアパタイト、またはCa欠損ヒドロキシアパタイト(CDHA)を含む、請求項14に記載のリン酸カルシウムセメント組成物。
- 成分B中のリン酸カルシウム粉末の量が0.4g/mL以上、好ましくは1.0g/mLより大きい、請求項14または15に記載のリン酸カルシウムセメント組成物。
- リン酸カルシウム粉末の粒子はナノ結晶、好ましくは100nmの平均直径を有するナノ結晶である、請求項14から16のいずれか一項に記載のリン酸カルシウムセメント組成物。
- 成分AもしくはBまたはその両方が少量の水溶性ポリマーを含む、請求項1から17のいずれか一項に記載のリン酸カルシウムセメント組成物。
- ポリマーが、(i)ヒアルロナン、好ましくはヒアルロン酸ナトリウムまたはヒアルロン酸;(ii)硫酸コンドロイチン;(iii)セルロース誘導体、好ましくはヒドロキシプロピルメチルセルロースまたはメチルセルロース;(iv)ポリビニルピロリドン;(v)N−メチル−2−ピロリドンまたは(vi)ジメチルシロキサン;(vii)アルギン酸塩、(viii)キトサン、(ix)ゼラチン、(x)コラーゲンからなる群から選択される、請求項18に記載のリン酸カルシウムセメント組成物。
- ポリマーの量が少なくとも0.1重量%、好ましくは少なくとも0.3重量%である、請求項18または19に記載のリン酸カルシウムセメント組成物。
- ポリマーの量が多くとも3.0重量%、好ましくは多くとも2.0重量%である、請求項18または19に記載のリン酸カルシウムセメント組成物。
- 以下の群、即ち、(i)ヨウ素系溶液、好ましくは、イオヘキソール、イオジキサノールおよびイオベルソール;(ii)金属粉末、好ましくはTa、または(iii)セラミック、好ましくは炭化タングステン、酸化ビスマスまたは酸化ジルコニウムから選択された放射線乳白剤をさらに含む、請求項1から21のいずれか一項に記載のリン酸カルシウムセメント組成物。
- 成分AおよびBの混合時のリン酸カルシウム対液体の重量比が2以上である、請求項1から22のいずれか一項に記載のリン酸カルシウムセメント組成物。
- 成分BのpHが6以下、好ましくは5未満である、請求項1から23のいずれか一項に記載のリン酸カルシウムセメント組成物。
- 成分BのpHが弱酸を使用して、好ましくは、酢酸、ギ酸、乳酸、クエン酸、及びプロピオン酸を使用して調整される、請求項1から24のいずれか一項に記載のリン酸カルシウムセメント組成物。
- 成分B中の弱酸の濃度が0.1M以上、好ましくは0.2Mより大きい、請求項25に記載のリン酸カルシウムセメント組成物。
- 成分AのpHが8より大きく、好ましくは9より大きい、請求項1から26のいずれか一項に記載のリン酸カルシウムセメント組成物。
- α−リン酸三カルシウムは80%を超える、好ましくは90%を超える純度を有する、請求項5から27のいずれか一項に記載のリン酸カルシウムセメント組成物。
- α−リン酸三カルシウムがアパタイトで汚染されている、請求項28に記載のリン酸カルシウムセメント組成物。
- α−リン酸三カルシウムが0.5m2/gより大きい、好ましくは2.0m2/gより大きい比表面積(SSA)を有する、請求項5から29のいずれか一項に記載のリン酸カルシウムセメント組成物。
- 2つの別個の部屋CAおよびCBを有する装置であって、これらの部屋の内容物を2つの部屋間の分離を除去する際に混合することができ、部屋CAは請求項1から30のいずれか一項の成分Aを含み、部屋CBは請求項1から30のいずれか一項の成分Bを含む、装置。
- 成分Aと成分Bの体積比A/Bが8:1から12:1の範囲である、請求項31に記載の装置。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CH2013/000068 WO2014172794A1 (en) | 2013-04-22 | 2013-04-22 | Calcium phosphate cement composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016516513A true JP2016516513A (ja) | 2016-06-09 |
JP6182259B2 JP6182259B2 (ja) | 2017-08-16 |
Family
ID=48288692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016509243A Expired - Fee Related JP6182259B2 (ja) | 2013-04-22 | 2013-04-22 | リン酸カルシウムセメント組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9611173B2 (ja) |
EP (1) | EP2988789B1 (ja) |
JP (1) | JP6182259B2 (ja) |
AU (1) | AU2013387611B2 (ja) |
WO (1) | WO2014172794A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021067502A1 (en) * | 2019-09-30 | 2021-04-08 | Saudi Arabian Oil Company | Systems and methods for high temperature, high pressure isothermal calorimetry |
EP4169608A1 (de) | 2021-10-25 | 2023-04-26 | Heraeus Medical GmbH | Vorrichtung zum bereitstellen einer flüssigkeitskomponente eines knochenzementteigs, system und verfahren zum bereitstellen eines knochenzementteigs |
EP4197494A1 (de) | 2021-12-17 | 2023-06-21 | Heraeus Medical GmbH | Augmentationsvorrichtung, komposit und verfahren zur herstellung eines komposits |
EP4226897B1 (de) | 2022-02-11 | 2024-07-03 | Heraeus Medical GmbH | Augmentationsvorrichtung |
EP4335466A1 (de) | 2022-09-08 | 2024-03-13 | Heraeus Medical GmbH | Zusammensetzung zur herstellung eines knochenersatzmaterials, verfahren zur herstellung eines pharmazeutischen wirkstoffträgers, pharmazeutischer wirkstoffträger sowie dessen verwendung |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003516190A (ja) * | 1999-12-09 | 2003-05-13 | ドクトル.ハー.ツェー.ロベルト マシーズ スティフツング | マグネシウム塩で安定化されたブラッシュ石水硬セメント |
US20040244651A1 (en) * | 2001-11-14 | 2004-12-09 | Lemaitre Jacques | Pasty or liquid multiple constituent compositions for injectable calcium phosphate cements |
JP2006289092A (ja) * | 2005-04-08 | 2006-10-26 | Howmedica Leibinger Inc | リン酸カルシウム系セメント |
JP2012524821A (ja) * | 2009-12-18 | 2012-10-18 | ハウメディカ・オステオニクス・コーポレイション | 照射後貯蔵安定性の直接注入可能なデュアルペースト型骨セメントを製造するシステムおよびリン酸カルシウム組成物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7163651B2 (en) * | 2004-02-19 | 2007-01-16 | Calcitec, Inc. | Method for making a porous calcium phosphate article |
DE602005014688D1 (de) * | 2005-11-15 | 2009-07-09 | Robert Mathys Foundation Dr H | Knochenreparaturmaterial |
-
2013
- 2013-04-22 WO PCT/CH2013/000068 patent/WO2014172794A1/en active Application Filing
- 2013-04-22 JP JP2016509243A patent/JP6182259B2/ja not_active Expired - Fee Related
- 2013-04-22 US US14/785,818 patent/US9611173B2/en active Active
- 2013-04-22 AU AU2013387611A patent/AU2013387611B2/en active Active
- 2013-04-22 EP EP13720218.0A patent/EP2988789B1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003516190A (ja) * | 1999-12-09 | 2003-05-13 | ドクトル.ハー.ツェー.ロベルト マシーズ スティフツング | マグネシウム塩で安定化されたブラッシュ石水硬セメント |
US20040244651A1 (en) * | 2001-11-14 | 2004-12-09 | Lemaitre Jacques | Pasty or liquid multiple constituent compositions for injectable calcium phosphate cements |
JP2006289092A (ja) * | 2005-04-08 | 2006-10-26 | Howmedica Leibinger Inc | リン酸カルシウム系セメント |
JP2012524821A (ja) * | 2009-12-18 | 2012-10-18 | ハウメディカ・オステオニクス・コーポレイション | 照射後貯蔵安定性の直接注入可能なデュアルペースト型骨セメントを製造するシステムおよびリン酸カルシウム組成物 |
Also Published As
Publication number | Publication date |
---|---|
AU2013387611A1 (en) | 2015-11-12 |
EP2988789A1 (en) | 2016-03-02 |
US20160075599A1 (en) | 2016-03-17 |
AU2013387611B2 (en) | 2017-06-01 |
EP2988789B1 (en) | 2018-05-09 |
US9611173B2 (en) | 2017-04-04 |
WO2014172794A1 (en) | 2014-10-30 |
JP6182259B2 (ja) | 2017-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6182259B2 (ja) | リン酸カルシウムセメント組成物 | |
Schumacher et al. | Strontium modified calcium phosphate cements–approaches towards targeted stimulation of bone turnover | |
JP4940126B2 (ja) | 外科用のリン酸カルシウムをベースとする水硬セメント | |
AU2006201475B2 (en) | Calcium phosphate cement | |
CA2901528C (en) | Heat-treated, sintered and micronized hydroxyapatite powder for use in a hardenable bone substitute composition | |
CN1826145B (zh) | 改进的磷酸钙骨水泥 | |
Bae et al. | Effects of high-energy ball-milling on injectability and strength of β-tricalcium-phosphate cement | |
US8287641B2 (en) | Calcium phosphate particles and hydraulic cements based thereon | |
US20130066327A1 (en) | Hydraulic cement compositions with low ph methods, articles and kits | |
RU2643337C1 (ru) | Резорбируемый рентгеноконтрастный кальций-фосфатный цемент для костной пластики |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160413 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170314 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170608 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170627 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170721 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6182259 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |